ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
about
CAR models: next-generation CAR modifications for enhanced T-cell functionImmune Cells in Cancer Therapy and Drug DeliveryChimeric antigen receptor T-cell therapy for solid tumorsDifferent Subsets of T Cells, Memory, Effector Functions, and CAR-T ImmunotherapyMesothelin-Targeted CARs: Driving T Cells to Solid TumorsChimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetCAR T Cell Therapy: A Game Changer in Cancer TreatmentNovel immunotherapies for hematologic malignanciesUsing gene therapy to manipulate the immune system in the fight against B-cell leukemiasTh17 Cell Plasticity and Functions in Cancer ImmunityExploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinicSmart CARs engineered for cancer immunotherapyβ-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cellsIdentification and selective expansion of functionally superior T cells expressing chimeric antigen receptorsAffinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in MicePotential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cellsImproving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cellsChimeric antigen receptor-modified T cells strike back.Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.Humanized Mouse Models of Clinical Disease.Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.Global Manufacturing of CAR T Cell Therapy.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce ToxicityChimeric Antigen Receptor (CAR) therapy for multiple myeloma.Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets.The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.The Principles of Engineering Immune Cells to Treat Cancer.
P2860
Q26745600-5B47FA1F-321D-455D-A16B-B1C1BD892222Q26747061-4E7CDAAA-77A4-4C77-BC0C-372EA0ADDAC4Q26750908-687047AC-ACC0-4E98-8708-9201FB73F4A7Q26752955-3D71811A-7FA1-479E-A8F7-2D5864CB6194Q26778759-F167FB78-54BF-4F3D-BCAD-27E7DC6541DCQ26799357-0EB96ABE-5E8E-4F9B-9FFF-E60784E77F3AQ26822769-71A39CC1-1E0E-41FD-BDBD-E3745C4ABDF9Q27004436-A9A43042-0B79-4715-8324-D4E861A6935FQ27011297-CE76C659-04B5-4281-B641-F6EDD2930F06Q27012901-277A7886-216B-4B90-B0D2-A0FA6CB60F24Q28075992-296D22DB-E98B-4D91-9EC2-1E77588726BBQ28087236-E30082DD-0F6F-4BAE-8A78-DC804B2369DAQ33578997-A1C7B42B-E5A8-4401-A379-430415055B0BQ33671867-D705522F-15B6-460F-BB1A-E41CAD981AB3Q34553167-8B810533-ED49-4C1B-A281-9E4A197982ABQ35328354-68BAFDCC-D427-4B81-A30B-A3520D4DF387Q35689938-393B4321-911C-4DDF-B5FC-47803F970539Q36028047-69398EA7-983B-4301-9903-EB280D8C3456Q36212699-6D2319A0-6B1E-4A63-A9D1-7D240B2904FEQ36777093-681A5A9F-ECED-4144-9659-0A79906D2957Q37040370-169E7E53-379D-4D7C-897B-CC5AD710DDB7Q37592957-D37512CC-B528-42AD-81A4-84FC121EF77DQ37614202-ED1BCB06-F679-4391-9171-E84950C0A6B2Q37713686-03990F18-E1E0-4159-BDAA-EBF980DE3355Q37717884-D8D21AA3-CD73-4FD2-9BAB-EC967786C34FQ38289029-98DFDBEF-F17D-4B0B-A25A-CBA2776D305EQ38304438-54F31E6E-D2BF-40B5-8316-D1BD1A576A57Q38525024-639BC39A-E9B2-408B-B95E-3E52F0E1B7E9Q38640367-A064AAE9-5951-4422-A6FD-6EE2CFC1B0E1Q38704573-E5F4FE8B-C7C7-426B-9553-D1D5B0A4AD01Q38735074-2EDA2CA3-90E4-4B90-BFCC-3D97BD84CEDEQ38748836-4E93D007-0A2B-4B2E-A9A1-F74114F56660Q38769271-884C62CD-3680-4BAE-B21E-9A7198A56489Q38775177-D42EC2F0-8797-47A4-8246-8F7AF2481609Q38830813-ED2FC1B4-9D26-4586-808E-6739A4BBA30FQ38913549-E76E9827-89F2-41BA-A6BC-3D0CA723C356Q38951943-0EC72656-F71F-45B1-9956-539E0A987E08Q38957129-5AC03962-1A05-415C-8740-7951D57279D6Q39039017-490E1E90-9382-4A50-AAE1-2D1689B30323Q39130457-5366DD9E-805B-45C2-BAE0-9146C997AE88
P2860
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@ast
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@en
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@nl
type
label
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@ast
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@en
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@nl
prefLabel
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@ast
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@en
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@nl
P2093
P2860
P1433
P1476
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
@en
P2093
Avery D Posey
Aviv Madar
Carl H June
Carmine Carpenito
Jihyun Lee
John Scholler
Matthew J Frigault
Nathalie Scholler
Richard Bonneau
Sonia Guedan
P2860
P304
P356
10.1182/BLOOD-2013-10-535245
P407
P577
2014-07-01T00:00:00Z